Sometimes drugs need a bigger push to be more effective and reach their final destination: the brain. The three families of peptides (proteins) developed and patented by Gate2Brain fulfill this mission by acting as a shuttle or tractor for drugs to act on this organ and treat localized pathologies.
This development led by Meritxell Teixidó, CEO of the company, after several years of work, has been possible thanks to a team of researchers and professionals from the University of Barcelona, IRB Barcelona and Hospital Sant Joan de Déu. The first application of this technology will be for the treatment of pediatric cancer, when it is located in the brain.
“We are currently in the preclinical phase and the first clinical trial with pediatric patients is scheduled for 2026, at the Sant Joan de Déu Hospital, a reference center for childhood diseases”, explains Teixidó. The company has recently drawn the attention from the EIC Accelerator program of the European Union, which has injected 2.5 million euros into it.
Source: Expansión Start Up